CRISPR-U™ Gene Knockout Cell Line
Strategy
JAK2 Gene Knockout Strategy
CRISPR-U™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With CRISPR-U™, Ubigene has
successfully edited over 3000 genes on more than 100 types of cell lines.
Objective
To create a Human JAK2 Knockout
model in cell line by
CRISPR-U™-mediated
genome
engineering.
Target gene info 
| Official symbol | JAK2 |
| Gene id | 3717 |
| Organism | Homo sapiens |
| Official full symbol | Janus kinase 2 |
| Gene type | protein-coding |
| Also known as | JTK10 |
| Summary | This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. |
| Genomic regions | Chromosome 9 |
Strategy Summary
This gene has 3 protein coding transcripts：
| Name | Transcript ID | bp | Protein | Biotype | CCDS | UniProt Match | RefSeq Match | Flags |
| JAK2-201 | ENST00000381652.4 | 7023 | 1132aa | Protein coding | CCDS6457 | O60674 | NM_004972.4 | TSL:1, GENCODE basic, APPRIS P1, MANE Select v0.92, |
| JAK2-204 | ENST00000636127.1 | 2615 | 710aa | Protein coding | - | A0A1B0GTR9 | - | CDS 3' incomplete, TSL:5, |
| JAK2-202 | ENST00000476574.5 | 327 | 26aa | Protein coding | - | A0A1B0GVR5 | - | CDS 3' incomplete, TSL:3, |
| JAK2-203 | ENST00000487310.1 | 773 | No protein | Processed transcript | - | - | - | TSL:2, |
Red Cotton™ Assessment
Project Difficulty Level unknown
| Target Gene | JAK2 |
| This KO Strategy | loading |
| Red Cotton™ Notes | Gene JAK2 had been KO in hela cell line. |
Aforementioned information comes from Ubigene database. Different origin of cell lines may have
different condition. Ubigene reserved all the right for final explanation.
Special deals for this gene:
$39
Single gRNA plasmid off-shelf
$599
Single gRNA lentivirus
Work flow
Comment: